Xylocor sees enough to press on with angina gene therapy
A pivotal trial is in the works, but can the group succeed where other VEGF gene therapies have failed?
The world's twelfth VEGF drug will be sold by Takeda
The Japanese company keeps the licensing fires burning with a $400m deal for Hutchmed’s fruquintinib.
Lantheus has three shots on goal to challenge Novartis
Two days after tying up with Point the company outlines plans to dominate PSMA-based prostate cancer screening and treatment.
Lantheus gets to the Point in therapeutics
Lantheus goes further into radioligand therapeutics, but the market thinks its latest push shortchanges Point Biopharma.
Go or no go? GSK takes its turn with a novel anaemia class
Amicus and Astrazeneca have notable approaching Pdufa decisions, while a panel for GSK’s daprodustat could change the course of a controversial drug class.
Ocular Therapeutix joins the long-acting race
But the group has a long way to go to set up a showdown with Eylea.
